| |
PRZOOM - /newswire/ -
Cambridgeshire, United Kingdom, 2009/07/06 - Quotient Clinical, a strategic business unit of leading drug development services provider Quotient Bioresearch, today announces that it has been awarded Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).
|
| |
This is one of the highest levels of accreditation in Europe and confirms that Quotient Clinical is qualified to perform the full range of Phase I trials, including First-in-Human (FIH) studies for low molecular weight chemical entities and biologics.
The MHRA voluntary accreditation scheme was introduced in April 2008 in line with recommendations from the MHRA clinical trial expert advisory group, to maximise subject safety, and provides formal guidance on the standards expected in a clinical unit conducting FIH studies.
Mark Egerton, Managing Director of Quotient Clinical comments, "Our MHRA Supplementary Accreditation provides volunteers and sponsors with additional reassurance of the high standards we apply in performing clinical studies. This award acknowledges our continued commitment to quality and safety and underpins our status as one of the leading clinical units in Europe."
With a highly skilled staff of 160 and a 100 bed capacity, Quotient Clinical offers a unique streamlined process to reduce the time from First-in-Man studies through to proof-of-concept, integrating flexible drug product manufacture into clinical trials. As a specialist in early development services, the company applies new technologies and expertise to speed the drug development process. Quotient Clinical serves a broad range of customers from global pharmaceutical companies to small biotechs worldwide and is considered a leading provider of early phase studies in the UK.
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. T: +44 1477 539 539 F: +44 1477 539 540 E: quotient[.]scottpr.com.
About Quotient Clinical
Quotient Clinical is a strategic business unit of Quotient Bioresearch. It was formed in May 2009 following the acquisitions of two companies, Charles River Laboratories' Edinburgh clinical research facility in May 2009 (formerly Inveresk Clinical Research) and Pharmaceutical Profiles in December 2008. Quotient Clinical specialises in early clinical drug development, and offers a unique streamlined process to reduce the time from First-in-Man studies through to proof of concept, integrating flexible drug product manufacture into clinical trials. With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a unique and comprehensive range of early development services to a broad range of pharmaceutical and biotechnology customers.
About Quotient Bioresearch
Quotient Bioresearch (quotientbioresearch.com) is part of the Quotient Bioscience group. The Quotient Bioscience group comprises Quotient Bioresearch, HFL Sport Science and Alba Bioscience. Quotient Bioresearch provides a range of specialist, early-stage drug development services; HFL Sport Science is the world's premier drug surveillance and doping control laboratory for sport; and Alba Bioscience is one of the world's leading manufacturers of monoclonal reagents for blood typing. Quotient Bioscience has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Further acquisitions are anticipated with a view to offering clients a broader, unified range of services.
|
clinical[.]quotientbioresearch.com 
